Apotex Asks High Court To Consider Commercial Marketing Notice To Product Sponsor
(September 30, 2016, 9:20 AM EDT) -- WASHINGTON, D.C. — Apotex Inc. and Apotex Corp. (collectively, Apotex) ask the U.S. Supreme Court in a Sept. 9 petition for writ of certiorari to decide if the Federal Circuit U.S. Court of Appeals erred in holding that biosimilar applicants must provide a product sponsor with a notice of commercial marketing under the Biologics Price Competition and Innovation Act (BPCIA) (Apotex Inc. and Apotex Corp. v. Amgen Inc. and Amgen Manufacturing Ltd., No. 16-332, U.S. Sup.).
(Petition for writ of certiorari available. Document #78-161003-003B.)